Brief description not available

Researchers at UCLA have developed novel nanocapsules that preferentially direct protein delivery to the intracellular space of cells. The invention overcomes the major challenge of stability for protein-based therapeutics.

Researchers in UCLA’s Department of Medicine have developed a novel peptide bridging technology that is a more efficient and cost-effective alternative to stapling technology for the manufacturing of peptide therapeutics. 

UCLA researchers under the guidance of Drs. Matthew Rettig and Mike Jung have developed a novel family of therapeutics for use against castration resistant prostate cancer. These drugs have been shown to inhibit the androgen receptor and are unaffected by the most common drug-resistant mutations found in prostate cancer patients.

Researchers in UCLA Department of Dermatology have demonstrated through in vitro experiments that resveratrol, an ingredient in antioxidants and anti-aging products, generates sustained bactericidal and anti-inflammatory effects against P. acnes, the bacteria involved in the pathogenesis of acne.

Researchers at UCLA's Jonsson Comprehensive Cancer Center have identified a naturally occurring human protein, apolipoprotein (ApoA-I), which helps kill ovarian cancer cells and improves overall survival. Experimental data suggest that apoA-I and apoA-I mimetic peptides are promising therapeutic agents for the treatment of human ovarian cancer. The powerful anti-cancer effect of apoA-I is demonstrated with strong inhibition of tumor growth and spreading in animal models of ovarian cancer.

UCLA scientists have developed an automated microfluidic platform that uses on-chip hydrogen-deuterium exchange (HDX) coupled with mass spectrometry (MS) to characterize protein structure.

UCLA researchers have designed and produced a series of small peptides that demonstrate outstanding synergistic efficacy with radiation in treating tumor growth and development. In addition, the peptides are potent inhibitors of viral infection from HIV and herpes simplex virus (HSV).

Brief description not available

UCLA researchers in the School of Medicine have developed a series of novel estrogen receptor antagonists for breast cancer therapy.

UCLA researchers in the Department of Neurology with an international team of scientists have developed compounds for therapeutic use in protein misfolding diseases.

Researchers in UCLA Department of Molecular & Medical Pharmacology have used a rapid, live virus assay to develop potent enterovirus inhibitors.

Brief description not available

UCLA researchers have developed antibody-interferon fusion proteins that show high efficacy against cancer cells in vitro and in vivo.

Investigators at UCLA have discovered a series of small molecules to facilitate therapeutic exon skipping. The use of these identified molecules may enhance the effectiveness of antisense oligonucleotide agents currently in clinical development.

Brief description not available

Brief description not available

Brief description not available

Brief description not available

UCLA researchers have invented a method of decreasing myocardial injury and infarct size through the intravenous administration of the netrin-1 or netrin-1-derived peptides during a cardiac event. These agents have powerful cardioprotective effects and provide a novel and effective therapy for the treatment of myocardial infarction.

UCLA researchers in the Department of Medicine have discovered that administration of small molecule inhibitors of ENPP1 or functional antagonists of PPi can substantially attenuate ectopic calcification. This suggests that ENPP1 and PPi can be potential pharmacological targets when developing therapeutics for pathological ectopic calcification.

UCLA has a robust intellectual property position on antibody-based diagnostics and therapeutics against N-cadherin for the treatment and detection of prostate and bladder cancers. The research and development leading to this promising technology has been conducted by Dr. Robert Reiter, Professor of Urology and Director of UCLA’s Prostate Cancer Program.

Brief description not available

Dr. Manuel Penichet and colleagues at the UCLA Departments of Surgery and Microbiology, Immunology, and Molecular Genetics have developed a novel anti-human transferrin receptor (TfR) antibody for the treatment of incurable hematological malignancies such as multiple myeloma and aggressive lymphoma.

Researchers at UCLA have developed a highly stable neuromedin U (NMU) analog for the treatment of obesity and type 2 diabetes.